[ET Net News Agency, 8 September 2021] Credit Suisse lowered its target price for Luye
Pharma (02186) to HK$4.8 from HK$6.8 and downgraded its rating to "neutral" from
"outperform".
The research house said it revises down FY21/22/23 revenue estimates by -6%/-7%/-7%
mainly due to adjusted product sales of 2021. It also revises down FY21/22/23E EPS by
10%/19%/21% due to lower margin profile. (RC)